Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-03

Study Completion Date

2028-07-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

NCT04566978

Large B-cell Lymphoma DLBCL

COMPLETED EARLY_PHASE1

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

NCT06811272

Relapsed Large B-cell Lymphoma Refractory Large B-cell Lymphoma

RECRUITING PHASE2

Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma

NCT00897923

Lymphoma Small Intestine Cancer

COMPLETED

Testing a Personalize Medication Log for Patients With Lymphoma

NCT02370446

Lymphoma

COMPLETED

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

NCT05861050

Blastoid Variant Mantle Cell Lymphoma Mantle Cell Lymphoma Pleomorphic Variant Mantle Cell Lymphoma

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma, B-Cell Lymphoma Large-cell Lymphoma Large B-cell Lymphoma DLBCL - Diffuse Large B Cell Lymphoma Mediastinal B-Cell Diffuse Large Cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hematologists

Hematologists will be recruited from the lymphoma clinics at MSK

Group Type EXPERIMENTAL

Hematolo-GIST Training

Intervention Type BEHAVIORAL

Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.

Participants Patients

Participant patients are being treated by a hematologic oncologist participating in this study

Group Type EXPERIMENTAL

Participants Appointment

Intervention Type BEHAVIORAL

Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hematolo-GIST Training

Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.

Intervention Type BEHAVIORAL

Participants Appointment

Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Providers

* Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)

Patients

* Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
* Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
* Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)
* Self-identify as Black and/or White
* Per medical record, 18 years of age or older
* Per self-report, fluent in English\*\*

* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:

1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
2. What is your preferred language for healthcare? (must respond English)

Exclusion Criteria

Providers

* Per self-report, planning to leave the cancer center in the next 12 months

Patients

* Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
* Per research staff judgment and/or self-report, too ill or weak to complete study procedures
* Per medical record or self-report, receiving hospice care at the time of enrollment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No